These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 11587184

  • 1. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [Abstract] [Full Text] [Related]

  • 2. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C.
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
    Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY.
    Int J Pept Protein Res; 1995 Oct; 46(3-4):244-52. PubMed ID: 8537178
    [Abstract] [Full Text] [Related]

  • 4. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M, Cheng LL, Stoev S, Bankowski K, Przybyiski J, Klis WA, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1995 Oct; 1(1):66-79. PubMed ID: 9222985
    [Abstract] [Full Text] [Related]

  • 5. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
    Manning M, Cheng LL, Klis WA, Balaspiri L, Olma A, Sawyer WH, Wo NC, Chan WY.
    J Med Chem; 1995 May 12; 38(10):1762-9. PubMed ID: 7752199
    [Abstract] [Full Text] [Related]

  • 6. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY, Wo NC, Cheng LL, Manning M.
    J Pharmacol Exp Ther; 1996 May 12; 277(2):999-1003. PubMed ID: 8627583
    [Abstract] [Full Text] [Related]

  • 7. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
    Manning M, Kruszynski M, Bankowski K, Olma A, Lammek B, Cheng LL, Klis WA, Seto J, Haldar J, Sawyer WH.
    J Med Chem; 1989 Feb 12; 32(2):382-91. PubMed ID: 2913298
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Pept Sci; 1999 Nov 12; 5(11):472-90. PubMed ID: 10587312
    [Abstract] [Full Text] [Related]

  • 9. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M, Cheng LL, Stoev S, Klis W, Nawrocka E, Olma A, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1997 Nov 12; 3(1):31-46. PubMed ID: 9230469
    [Abstract] [Full Text] [Related]

  • 10. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S, Cheng LL, Olma A, Klis WA, Manning M, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1999 Mar 12; 5(3):141-53. PubMed ID: 10323558
    [Abstract] [Full Text] [Related]

  • 11. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
    Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH.
    J Pept Sci; 2006 Sep 12; 12(9):592-604. PubMed ID: 16625682
    [Abstract] [Full Text] [Related]

  • 12. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
    Manning M, Misicka A, Olma A, Klis WA, Bankowski K, Nawrocka E, Kruszynski M, Kolodziejczyk A, Cheng LL, Seto J.
    J Med Chem; 1987 Dec 12; 30(12):2245-52. PubMed ID: 2960812
    [Abstract] [Full Text] [Related]

  • 13. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
    Chan WY, Wo NC, Stoev ST, Cheng LL, Manning M.
    Exp Physiol; 2000 Mar 12; 85 Spec No():7S-18S. PubMed ID: 10795902
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct.
    Ammar A, Roseau S, Butlen D.
    Am J Physiol; 1992 Apr 12; 262(4 Pt 2):F546-53. PubMed ID: 1533099
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M, Stoev S, Bankowski K, Misicka A, Lammek B, Wo NC, Sawyer WH.
    J Med Chem; 1992 Jan 24; 35(2):382-8. PubMed ID: 1531076
    [Abstract] [Full Text] [Related]

  • 16. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Jan 24; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 17. Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin.
    Manning M, Bankowski K, Barberis C, Jard S, Elands J, Chan WY.
    Int J Pept Protein Res; 1992 Jan 24; 40(3-4):261-7. PubMed ID: 1478783
    [Abstract] [Full Text] [Related]

  • 18. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
    Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng LL, Chan WY, Wo NC, Sawyer WH.
    J Med Chem; 1992 Oct 16; 35(21):3895-904. PubMed ID: 1433200
    [Abstract] [Full Text] [Related]

  • 19. Barusiban suppresses oxytocin-induced preterm labour in non-human primates.
    Reinheimer TM.
    BMC Pregnancy Childbirth; 2007 Jun 01; 7 Suppl 1(Suppl 1):S15. PubMed ID: 17570159
    [Abstract] [Full Text] [Related]

  • 20. Receptors for neurohypophyseal hormones along the rat nephron: 125I-labelled d(CH2)5[Tyr(Me)2, Thr4, Orn8, Tyr-NH(2)9] vasotocin binding in microdissected tubules.
    Ammar A, Schmidt A, Semmekrot B, Roseau S, Butlen D.
    Pflugers Arch; 1991 Apr 01; 418(3):220-7. PubMed ID: 1830390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.